Insperity (NSP)
(Delayed Data from NYSE)
$93.01 USD
-0.42 (-0.45%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $92.99 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.01 USD
-0.42 (-0.45%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $92.99 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Zacks News
Insperity (NSP) Q3 Earnings Beat Estimates, Stock Up 2.5%
by Zacks Equity Research
Insperity's (NSP) third-quarter 2020 results reflect outperformance in worksite employee growth and pricing.
Insperity's (NSP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Insperity (NSP).
Zacks Industry Outlook Highlights: Robert Half International, Insperity and Kforce
by Zacks Equity Research
Zacks Industry Outlook Highlights: Robert Half International, Insperity and Kforce
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
by Zacks Equity Research
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
Pick These 5 Stocks With Superb Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.
3 Stocks From the Promising Staffing Space to Watch Out For
by Sanjana Goswami
The coronavirus-driven dependency on technology, abrupt shift in recruitment patterns within the industry and reduction in expenses should help the Zacks Staffing industry thrive. RHI, NSP and KFRC are well positioned to witness demand surge.
Staffing Industry Up 30.4% in Past 6 Months: Stocks in Focus
by Sanjana Goswami
Coronavirus-induced strict lockdowns and market uncertainties lead to an abrupt shift in recruitment patterns within the staffing industry.
Should Value Investors Now Choose Insperity (NSP) Stock?
by Zacks Equity Research
Let's see if Insperity (NSP) stock is a good choice for value-oriented investors right now from multiple angles.
Insperity (NSP) Beats on Q2 Earnings, Updates 2020 View
by Zacks Equity Research
Insperity's (NSP) second-quarter 2020 revenues reflect decline in average number of worksite employees paid per month.
Paychex (PAYX) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Paychex's (PAYX) fourth-quarter fiscal 2020 earnings and revenues decrease on a year-over-year basis.
FactSet (FDS) Beats Q3 Earnings Estimates, Lags Revenues
by Zacks Equity Research
FactSet's (FDS) third-quarter fiscal 2020 results benefit from higher sales of analytics, wealth management and content and technology solutions, and operating efficiency.
Accenture (ACN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Accenture's (ACN) third-quarter fiscal 2020 earnings and revenues decrease on a year-over-year basis.
ABM Industries (ABM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
ABM Industries (ABM) second-quarter fiscal 2020 earnings reflect margin improvement in Work Orders and operational efficiency.
H&R Block (HRB) Matches Q4 Earnings Estimate, Revenues Beat
by Zacks Equity Research
H&R Block, Inc.'s (HRB) fourth-quarter fiscal 2020 earnings and revenues declined year over year.
H&R Block's (HRB) Q4 Earnings, Revenues to be Hit by Coronavirus
by Zacks Equity Research
H&R Block's (HRB) Q4 results to reflect coronavirus-led reduction in the top and bottom lines.
DocuSign (DOCU) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DocuSign's (DOCU) first-quarter fiscal 2021 earnings and revenues expected to reflect year-over-year growth.
Slack (WORK) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The Atlassian acquisition is likely to have significantly benefited Slack's (WORK) paid customer growth in first-quarter fiscal 2021.
Coronavirus Crisis to Hurt Everi (EVRI) Q1 Earnings & Revenues
by Zacks Equity Research
Everi's (EVRI) Q1 results to reflect the unfavorable impact of coronavirus-led reduction in the top and bottom lines.
ABM Industries (ABM) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
ABM Industries' (ABM) second-quarter fiscal 2020 results to reflect the negative impact of the coronavirus-led reduction in the top and bottom lines.
ServiceMaster (SERV) Misses on Q1 Earnings, Withdraws View
by Zacks Equity Research
ServiceMaster's (SERV) first-quarter 2020 earnings decrease year over year.
Genpact (G) Beats Q1 Earnings Estimate Amid Coronavirus Crisis
by Zacks Equity Research
Genpact's (G) first-quarter 2020 earnings and revenues increase year over year.
Green Dot (GDOT) Beats on Q1 Earnings Amid Coronavirus Crisis
by Zacks Equity Research
Green Dot's (GDOT) first-quarter 2020 earnings decline but revenues increase year over year.
Stericycle (SRCL) Q1 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Stericycle's (SRCL) first-quarter 2020 earnings and revenues decline year over year.
Delphi Technologies (DLPH) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Delphi Technologies' (DLPH) first-quarter 2020 earnings and revenues decline year over year.
WEX's Q1 Earnings Miss Estimates Amid Coronavirus Crisis
by Zacks Equity Research
WEX's segments register year-over-year revenue growth in first-quarter 2020 on market-share expansion and recent acquisitions.